Thrombin Activatable Fibrinolysis inhibitor Thr 325 Ile polymorphism in fetuses with factor XIII deficient family history and Intracranial hemorrhage
Archives of Medical Laboratory Sciences,
Vol. 1 No. 3 (2015),
20 December 2015
https://doi.org/10.22037/amls.v1i3.10561
Abstract
Background: Factor XIII Deficiency (FXIIID) is an inherited rare bleeding disorder with some life threatening clinical manifestation including Intracranial Haemorrhage (ICH). Among all polymorphisms found in FXIIID, Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Thr325Ile gene polymorphism increases probability of ICH about 20 fold in patients with FXIII .So, in this study we aimed to evaluate TAFI Thr 325 Ile polymorphism in Chorionic villus samples (CVS) of fetuses with positive family history of FXIIID and ICH.
Materials and Methods: This study was performed on chorionic villus of pregnant mothers ´ with positive history of FXIIID accompanied with ICH in first-degree relatives of their fetus. All parents of the fetuses were completed consent form for doing Prenatal diagnosis (PND). Chorionic villus DNA was extracted from each sample using the DNA extraction kit and PCR-RFLP was performed for TAFI Thr 325Ile polymorphism in Exon 4 of FXIII A gene.
Results: All of 8 fetuses had positive family history of FXIIID. Seven out of eight fetuses (87.5%) had a family member with CNS bleeding due to FXIIID. Four fetuses had history of death due to FXIIID. There were 5 case (62.5%) that were homozygote for TAFI Thr 325 Ile, one (12.5%) was heterozygote and two (25%) were non mutant.
Conclusion: Detection of TAFI Thr 325 Ile polymorphism by PND program in fetuses with positive family history of ICH is seems necessary and it will help to fill many gaps in preventing life threatening features of FXIIID in newborn at the time of delivery by prophilaxy receiving and precautionary measures.
- Factor XIII deficiency
- intracranial hemorrhage
- TAFI Thr 325Ile
How to Cite
References
Naderi M, Dorgalaleh A, Alizadeh S, Kashani Khatib Z, Tabibian S, Kazemi A, Dargahi H, Bamedi T. Polymorphism of thrombin‐activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency. Haemophilia. 2014;20(1):e89-e92.
Naderi M, Dorgalaleh A, Alizadeh SH,Kazemi A,Dargahi H,Younedi MR,et al. Assessment of relationship between CNS bleeding in factor XIII deficiency and Thrombin- Activatable Fibrinolysis Inhibitor polymorphism. Arak Medical University Journal. 2013; 16(7): 83-90.
Naderi M, Dorgalaleh A,Alizadeh S,Kazemi A,Tabibian S,et al. Central Nervous System Bleeding in Factor XIII Deficiency, Assessment the Role of Plasminogen Activator Inhibitor-1. Journal of Isfahan Medical School. 2014; 31(263): 1985-1993.
Naderi M, Dorgalaleh A, Tabibian S, Alizadeh S, Eshghi P, Solaimani G. Current understanding in diagnosis and management of factor XIII deficiency. Iran J Pediatr Hematol Oncol. 2013; 3(4): 164-72.
Smith C.Intracranial haemorrhage in infants. Current Diagnostic Pathology, 2006. 12(3): 184-190.
Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin inThromb Hemost. 2009, 35(4):426-438.
Mosnier LO, Bouma BN.Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arteriosclerosis, thrombosis, and vascular biology, 2006. 26(11): 2445-2453.
Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41(3):323-9.
Naderi M, Esmaeili Reykande S, Dorgalaleh A, Alizadeh S, Einolahi N, Tabibian S, et al. Establishment of a prenatal diagnosis schedule as part of prophylaxis program of factor XIII deficiency in southeast of Iran. Blood coagulation and fibrionlysis. 2015.(in press)
Naderi M, Imani M, Eshghi P, Dorgalaleh A,Tabibian S, Alizadeh S,Sanei Moghadam E,Miri moghadam E. Factor XIII deficiency in Sistan and Baluchistan province. Sci J Blood Transfus Organ. 2013; 10(3): 282-288.
Naderi M, Alizadeh S, Kazemi A, Tabibian S, Zaker F, Bamedi T, Kashani Khatib Z, Dorgalaleh A. Central nervous system bleeding in pediatric patients with factor XIII deficiency: A study on 23 new cases. Hematology. 2015.20(2):112-8.
Majid N, Younesi MR, Dorgalaleh A, Alizadeh S, Kazemi A, Tabibian S. Association between expression of MMP-2 and MMP-9 genes and pathogenesis of intracranial hemorrhage in severe coagulation factor XIII deficiency. Hematology. 2015(in press)
Naderi M, Zarei T, Haghpanah S, Eshghi P, Miri-Moghaddam E, Karimi M. Intracranial hemorrhage pattern in the patients with factor XIII deficiency. Annals of hematology. 2014;93(4):693-7.
Peyvandi F, Tagliabue L, Menegatti M, Karimi M, Komáromi I, Katona É, Muszbek L, Mannuccio Mannucci P. Phenotype- genotype characterization of 10 families with severe a subunit factor XIII deficiency. Human mutation. 2004;23(1):98-108.
Akatsu H, Yamagata H, Chen Y, Miki T, Kamino K, Takeda M ,et al. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. British journal of haematology, 2004. 127(4): 440-447.
Tokgoz S, Zamani AG, Durakbasi-Dursun HG, Yilmaz O, Ilhan N, et al., TAFI gene polymorphisms in patients with cerebral venous thrombosis. Acta neurologica Belgica, 2013. 113(3): 291-297.
Kozian DH, Lorenz M, März W, Cousin E, Mace S, Deleuze J. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thrombosis & Haemostasis, 2010. 103(5): 976-983.
Kulkarni R, Lusher JM, Henrya RC,Kallen DJ.Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemophilia Foundation's Medical and Scientifc Advisory Council. Haemophilia .1999; 5;410-415.
Street AM, Ljung R, Lavery AM.Management of carriers and babies with haemophilia. Haemophilia .2008, 14 (3), 181–187.
Yoffe G, Buchanan GR. Intracranial hemorrhage in newborn and young infants with haemophilia. J Pediatr 1998 ;113: 333-6.
Ljung R, Lindgren AC, Petrini P et al. Normal vaginal delivery is to be recommended for haemophilia carrie gravidae. Acta Paediatr. 1994; 83: 6901-11.
Goldsmith JC, Kletzel M. Risk of birth related intracranial hemorrhage in haemophilic newborns: Results of a North American survey . Blood .1990;76: 421.
Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion (Paris). 2013;53(5):1120-31.
Killick CJ, Barton CJ, Aslam S, Standen G. Prenatal diagnosis in factor XIII-deficiency. Arch Dis Child Educ Pract Ed 1999;80(3): 238-9.
Archives
- Abstract Viewed: 115 times
- PDF Downloaded: 38 times